Most surveyed rheumatologists, nephrologists and primary care physicians cite increased use of Uloric (febuxostat), from Japan’s largest drugmaker Takeda (TYO: 4502), in the last six months. Global sales of Uloric reached 2 billion yen ($26 million yen) in the first fiscal quarter, up more than 50% year-on-year (The Pharma Letter August 2).
In addition, half of rheumatologists and 26% of nephrologists surveyed cite increased use of Savient Pharmaceuticals’ (Nasdaq: SVNT) Krystexxa (pegloticase) in the same time period, based on the recent TreatmentTrends: Gout report published by BioTrends Research, a Decision Resources unit. Uloric outperforms other uric acid lowering (UAL) therapies on most attributes including efficacy and short-term safety/tolerability while newcomer Krystexxa, which was approved in the USA last year (TPL September 15, 2010), holds only a single competitive advantage over Uloric.
Krystexxa rated highly satisfactory by 55% of rheumatologists
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze